Amalgamated Financial’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Amalgamated Financial’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$16K	Buy	+2,589	New	+$16.3K	﹤0.01%	2808

Other funds holding CDAK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.44B AUM 23.16% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Amalgamated Financial's CDAK Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2022: 2,589 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #2808 among its holdings.

62 funds tracked by Wall St. Rank hold CDAK as of Q1 2022.

Amalgamated Financial held 2,589 shares of Codiak BioSciences, Inc. Common Stock worth $16K as of Q1 2022.
Codiak BioSciences, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Codiak BioSciences, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2808 holding.
62 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.